mardi 13 juin 2017

Onco Actu du 13 juin 2017

3.3 Prévention - Vaccins

Merck CEO: Gardasil plus pipeline equals big things ahead for vaccines [FiercePharma]

4. Dépistage, diagnostic et pronostic

Talking to Patients About Cancer Screening Cessation [JAMA Internal Medicine]

4.1 Dép., diag. & prono. - Prostate

GPs leaving men with family history of prostate cancer 'blind' to the risks [The Telegraph]

4.2 Dép., diag. & prono. - Génome

Testicular cancer: men most at risk could be identified using new gene group [Reuters]

4.7 Dép., diag. & prono. - Col de l'utérus

6 things you need to know about cervical screening [Cancer Research UK]

5. Traitements

Already-promising cancer drug may have wider applicability [Dana-Farber Cancer Institute]

Antibiotics and vitamin C could kill cancer cells [NHS Choices]

Mini Particle Accelerators Make Cancer Treatment Safer for Everyone [Wired]

5.12.1 Immunothérapies - partenariats

Celgene bags option on NK cell-based blood cancer assets [FierceBiotech]

Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal [Xconomy]

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech [EndPoints]

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York [OSE]

5.12.2 Immunothérapies - CAR-T

New frontier in cancer care: Turning blood into living drugs [STAT]

CAR T Cells: Expanding into Multiple Myeloma [NCI]

5.12.3 Immunothérapies-combinaisons

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths [EndPoints]

In a Myeloma Setback, Merck Halts Studies Due to Patient Deaths [Xconomy]

Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies [Merck]

Merck to pause two late-stage studies testing Keytruda in myeloma [Reuters]

5.2 Pharma

Acceleron scraps dalantercept after it flunks a PhII test for kidney cancer [EndPoints]

5.2.3 Pharma - économie

Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory [EndPoints]

Supreme Court speeds copycat biologic drugs to market [Reuters]

5.4 Traitements - Economie

NICE backs Lartruvo for soft tissue sarcoma [PharmaTimes]

6.10.1 Politiques (USA)

Dr. Norman Sharpless Brings Proven Scientific Leadership to the National Cancer Institute [ASCO]

6.6 Publications

Empty rhetoric over data sharing slows science [Nature]

6.9 Controverses

Richard Smith: Is evidence based medicine a form of microfascism? [BMJ]

Conflicts of interest in health care journalism. Who’s watching the watchdogs? We are. Part 1 of 3 [HealthNewsReview]